Results 151 to 160 of about 221,455 (333)

Rituximab for refractory granulomatous eye disease

, 2012
Elyse E Lower1,2 Robert P Baughman,1 Adam H Kaufman31Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA; 2Oncology Hematology Care, Cincinnati, OH, USA; 3Department of Ophthalmology, University of Cincinnati, Cincinnati,
Baughman RP, Kaufman AH, Lower EE
core  

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development

Clinical and Developmental Immunology, 2008
We describe the effect on the neonate of administration of rituximab to a woman with idiopathic thrombocytopenic purpura (ITP). Rituximab, an anti-CD20 antibody, was given weekly for 4 weeks to a woman with ITP in her third trimester of pregnancy.
D. T. Klink, R. M. van Elburg, M. W. J. Schreurs, G. T. J. van Well   +3 more
doaj   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

American Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac, Audrey Bidet, Elise Chapiro, Nathalie Douet‐Guilbert, Jean‐Baptiste Gaillard, Nada Assaf, Nathalie Auger, Hend Chaker, Jasmine Chauzeix, Inge Govaerts, Hippolyte Guérineau, Christine Lefebvre, Pauline Roynard, Hélène Guermouche, Lucienne Michaux, Marie‐Bérengère Troadec, Lauren Véronèse   +16 more
wiley   +1 more source

Serum Chitotriosidase Links to Activated Glia at Chronic Active Lesion Rims in Multiple Sclerosis Brain

Annals of Neurology, EarlyView.
Objective The objective of this study was to explore the association between 18 kDa translocator protein (TSPO)‐positron emission tomography (PET)–measurable glial activation and serum chitotriosidase (CHIT1) in people with multiple sclerosis (pwMS), and its expression in postmortem MS brain tissue.
Venla Ahola, Maija Saraste, Edoardo Pedrini, Joel Tuomaala, Luzia Buchholz, Markus Matilainen, Johanna Lindenberg, Eeva‐Christine Brockmann, Maria Sofia Martire, Sofia Sandgren, David Leppert, Jens Kuhle, Tanja Kuhlmann, Martina Absinta, Laura Airas   +14 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma

HemaSphere
We report primary analysis results from the Phase 3 PERSPECTIVE study comparing ibrutinib + rituximab versus placebo + rituximab in patients with previously untreated follicular lymphoma requiring treatment per Groupe d'Etude des Lymphomes Folliculaires ...
David Belada, Faithlore P. Gardner, Ana C. de Oliveira, Juan‐Manuel Sancho, Elza Lomaia, David Wright, Mehmet Turgut, Elena Martynova, Zsolt Lázár, Bertrand Anz, Ming‐Chung Wang, Wojciech Legiec, Stephen Opat, Junvie Pailden, Hillary M. Peltier, Emerenziana Marturano, James P. Dean, Ian W. Flinn   +17 more
doaj   +1 more source

Reconstitution of the lymphocyte population in patients with pemphigus subjected to ''ultra low'' doses of rituximab

reserved1. Background: Il rituximab, un anticorpo monoclonale anti-CD20, si è rivelato una terapia efficace nel trattamento del pemfigo volgare, una grave patologia caratterizzata dal punto di vista patogenetico dalla presenza di autoanticorpi, e dal ...
MICELLO, GIUSEPPE
core  

Efficacy of high‐frequency low‐dose rituximab and acalabrutinib in chronic lymphocytic leukemia

HemaSphere
Anti‐CD20 monoclonal antibodies (mAbs) are effective but not curative treatment for chronic lymphocytic leukemia (CLL). To study rituximab efficacy, we examined serial blood samples from CLL patients receiving initial monotherapy with high‐frequency low ...
Charles C. Chu, Clare B. Heffernan, Nydia C. Jaimes‐Delgadillo, Christine A. Herne, Jennifer E. Bruno, Andrea M. Baran, John M. Ashton, Timothy R. Mosmann, Paul M. Barr, Ronald P. Taylor, Michael R. Elliott, Clive S. Zent   +11 more
doaj   +1 more source

Update on the use of rituximab for intractable rheumatoid arthritis

, 2009
R John LooneyUniversity of Rochester, Rochester, New York, USAAbstract: It has been 3 years since rituximab, a mouse x human chimeric anti-CD20 monoclonal antibody that selectively depleted B cells, was approved by the FDA for the treatment of moderate ...
R John Looney
core